Company: MBIO
Filing Date: 2025-12-23
Form Type: 8-K
Source: 0001104659-25-124189
Chunk: 1

Company: MUSTANG BIO, INC.
Filing Date: 2025-12-23
Form: 8-K
Item: Item 5.07
Chunk 1
---
359        99,071                     0  
  Manuel Litchman, M. D.           7,712,919       154,511                     0  
  Lindsay A. Rosenwald, M. D.      7,740,512       126,918                     0  
  Neil Herskowitz                  7,724,042       143,388                     0  
  David Jin                        7,769,563        97,867                     0  
  Adam Chill                       7,795,608        71,822                     0  
  Michael Zelefsky, M. D.          7,795,753        71,677                     0  

Proposal 2

The votes with respect to the ratification of KPMG LLP as Mustang’s independent registered accounting firm for the year ending December 31, 2025, were as follows:

  Total Votes For      Total Votes Against      Abstentions  
 ─────────────────────────────────────────────────────────────
        7,844,671                    9,814           12,945  

Proposal 3

The votes with respect to the approval of the amendment to the Company’s ESPP were as follows:

  Total Votes For      Total Votes Against      Abstentions  
 ─────────────────────────────────────────────────────────────
        7,815,313                   49,380            2,737  

Proposal 4

The votes with respect to the approval of an amendment to the Company’s EIP were as follows:

  Total Votes For      Total Votes Against      Abstentions  
 ─────────────────────────────────────────────────────────────
        7,664,161                  198,991            4,278  

Item 8.01 Other Events

As previously disclosed, Mustang Bio, Inc. (the “Company”) previously entered into that certain License Agreement with Fred Hutchinson Cancer Center (“ Fred Hutch”), dated as of May 17, 2017 (as amended, the “CD20 License Agreement”), under which the Company developed its CD20 CAR-T program. On December 17, 2025, the Company and Fred Hutch entered into a Termination and Release Agreement, pursuant to which: (i) the Company and Fred Hutch agreed to terminate the CD20 License Agreement; (ii) the Company agreed to pay Fred Hutch $730,000 as consideration for extinguishment of approximately $1.4 million in outstanding payables owing to Fred Hutch